BCG vaccine may rewire brain immunity, shift Alzheimer's markers over 12 months
· Medical Xpressedited by Stephanie Baum, reviewed by Robert Egan
Stephanie Baum
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
New research led by Mass General Brigham investigators suggests that the Bacillus Calmette-Guérin (BCG) vaccine—which is delivered through the skin to prevent tuberculosis—may remodel the human brain's immune environment, offering a potential biological explanation for previously observed associations between BCG vaccination and lower Alzheimer's disease risk. Findings are published in Communications Medicine.
The yearlong study found that BCG promoted increased responsiveness in immune cells surrounding the brain and modified Alzheimer's-related biomarkers in older adults without evidence of Alzheimer's pathology, but not in those with biomarker evidence of the disease.
"The immune system and the brain may be far more connected than we once thought," said senior and co-corresponding author Steven Arnold, MD, managing director of the Interdisciplinary Brain Center at Mass General Brigham Neuroscience Institute. "The next step is to test this rigorously in larger, controlled studies, particularly in prevention, where the hope would be to preserve brain health before significant Alzheimer's disease develops."
Earlier clues from BCG research
Over the last two decades, researchers at Mass General Brigham have been studying multiple "off-target" benefits of the BCG vaccine in autoimmunity and infection, including ongoing phase 3 clinical trials in type 1 diabetes and past phase 2 and phase 3 trials in COVID-19. Prior research involving preclinical models, retrospective studies and randomized clinical trials has suggested that BCG can also reduce Alzheimer's risk and bring about trained immunity, boosting defenses against unrelated infections and correcting blood sugars. Most prior research on trained immunity has focused on blood, leaving unclear whether BCG influences immune cells in the fluid surrounding the brain and spinal cord as well.
Seeking insight, the research team conducted two related one-year, open-label clinical trials of BCG immunotherapy in 23 adults 55 and older. The cohort included 12 adults with Alzheimer's pathology and 11 adults without. Cerebrospinal fluid (CSF) and peripheral blood samples were obtained from participants at regular intervals after vaccination.
The study, which was led by co-first authors Marc Weinberg, MD, Ph.D., Mahesh Chandra Kodali, Ph.D., and Zhaozhi Li, Ph.D., found that BCG promoted enhanced immune responses to other immune challenges, suggesting broader effects on immune function. Notably, the heightened immune responsiveness was not accompanied by an increase in inflammatory markers, which is a known risk factor for neurodegeneration.
A split effect on amyloid
BCG also shifted the levels of amyloid-beta (a key biomarker of Alzheimer's disease) in the CSF and bloodstream. In healthier participants without Alzheimer's disease pathology, amyloid levels declined significantly in brain and spinal fluid while increasing in blood samples over 12 months. This shift in balance was not observed in participants with Alzheimer's pathology, indicating no measurable effect in this group and suggesting that the timing of administering BCG might affect early disease dynamics and protein clearance from the central nervous system.
The authors note that further research, including placebo-controlled studies, is needed to investigate the relationship between BCG and Alzheimer's disease. They also noted that the study tested a specific vaccination strategy in older adults and does not examine the effect of BCG vaccination in childhood, which is common in many countries in sub-Saharan Africa, Southeast Asia and parts of Eastern Europe because of the prevalence of tuberculosis in these regions.
"Vaccines have traditionally been viewed through the lens of infectious disease prevention," said Weinberg, who contributed to the study while working as a research scientist at Mass General Brigham and is now an employee at AbbVie. "Although more research is needed, these findings suggest they may also influence biological processes involved in brain aging and neurodegenerative disease."
Publication details
Communications Medicine (2026). DOI: 10.1038/s43856-026-01691-7
Journal information: Communications Medicine
Key medical concepts
Alzheimer's DiseaseCerebrospinal Fluid
Clinical categories
NeurologyHealthy agingInfectious diseases Provided by Mass General Brigham Who's behind this story?
Stephanie Baum
Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: BCG vaccine may rewire brain immunity, shift Alzheimer's markers over 12 months (2026, July 2) retrieved 2 July 2026 from https://medicalxpress.com/news/2026-06-bcg-vaccine-rewire-brain-immunity.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.